ABVC
ABVC BioPharma Inc (ABVC)
Healthcare • NASDAQ • $0.92-1.57%
- Symbol
- ABVC
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.92
- Daily Change
- -1.57%
- Market Cap
- $24.50M
- Trailing P/E
- N/A
- Forward P/E
- -2.09
- 52W High
- $3.07
- 52W Low
- $0.71
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- 0.51
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, w…
Company websiteResearch ABVC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.